Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?
By the Top Tier Newswire AI Desk · August 5, 2026 at 9:42 AM ET · reviewed against 7 wire stories
TWIST BIOSCIENCE COR (TWST) is up +11.57% in the latest session. Our newswire has captured 7 stories on TWST across 4 sources in the last 36 hours, with AI sentiment reading bearish (avg 35/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TWST stock is up today
Twist Bioscience stock rose 11.57% to $110.96 in early trading on August 5 after the company priced an upsized $300 million public offering of 3.125 million common shares at $96 per share. The offering is expected to close on August 6 and will be used to fund research and development as well as manufacturing expansion. The stock opened at $99.23 and reached a session high of $111.69 shortly after the market opened.
What Happened
The company announced the upsized offering to raise $300 million, an increase from an earlier proposed $250 million offering. The offering includes an option for underwriters to purchase additional shares worth up to $37.5 million. The pricing of the offering at $96 per share, well above the company's 52-week low of $23.30, signaled strong investor confidence in the company’s growth strategy. The offering is expected to provide capital for R&D and manufacturing capacity expansion, reinforcing the company’s long-term innovation goals.
Retail traders on r/wallstreetbets are calling the stock oversold, citing its recent volatility and the company’s ongoing unprofitability. Meanwhile, Baird recently raised its price target for TWST to $115 and maintains an Outperform rating. The company’s recent quarterly earnings report showed a revenue beat but an EPS miss, which had previously caused the stock to decline.
What The Data Shows
The stock opened at $99.23 and climbed to $111.69 before settling at $110.96. The session volume of 0.3 million shares is 0.2 times the 3-month average. TWST has a market cap of $6.3 billion, with a trailing twelve-month revenue growth of 19.2% and a net margin of -31.7%. The stock has traded between $23.30 and $106.58 over the past 52 weeks. Over the last 8 sessions, it has risen 11.9% from $90.27 to $101.04. Recent insider transactions include multiple sales by executives, totaling $13.9 million in the last 90 days.
What To Watch
The company’s next key event is the closing of the $300 million offering on August 6. Investors will also be watching for any further updates on the company’s AI drug discovery pipeline and upcoming earnings reports.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TWST · Aug 5 session (5-min) · +15.81% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 7 stories · 35/100 bearish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
5d agoMarketChameleonBEARISH 28General
Twist Bioscience’s $300 Million Upsized Offering Targets Expansion—What Does It Signal for Growth Strategy?
Twist Bioscience has announced an upsized public stock offering, raising $300 million to fuel R&D and manufacturing expansion. This strategic move underlines the company's focus on innovation and growth. Here's a breakdown of the offering details, use of proceeds, and what investors should watch for as Twist positions itself for the future.
5d agoSeeking AlphaBEARISH 24General
Twist Bioscience prices upsized $300M equity at $96 per share
Twist Bioscience (TWST) priced an upsized underwritten public offering of 3.125M common shares at $96.00 per share.
5d agoStockTitanBEARISH 24General
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Shares are priced at $96 each; closing is expected Aug. 6, subject to conditions. Net proceeds are intended for research and manufacturing capacity.
5d agoSeeking AlphaBULLISH 57General
Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells
Conestoga Micro Cap Composite highlights top performers like Twist Bioscience and key portfolio shifts during Q2 2026. Read the full analysis for more details.
6d agoStockTitanBEARISH 24General
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist intends to grant underwriters an option for up to an additional $37.5 million in shares; the proposed offering remains subject to market and other conditions.
Some RSUs will vest over 48 months, with 25% vesting after one year for each employee; Nasdaq Rule 5635(c)(4) governs the inducement plan.
7d agoYahoo TopBEARISH 38Earnings
Twist Bioscience Shares Decline Following Quarterly Earnings Miss
Twist Bioscience shares fell after the company missed fiscal third-quarter earnings estimates despite reporting stronger-than-expected revenue, as investors remained focused on profitability trends.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →